Targeted delivery of a novel peptide–docetaxel conjugate to MCF-7 cells through neuropilin-1 receptor: reduced toxicity and enhanced efficacy of docetaxel

We have designed a novel peptide–docetaxel conjugate, which delivers docetaxel specifically to cancer cell targeting neuropilin-1 (NRP-1) receptor, thus enhancing its efficacy and acts more aggressively in breast cancer cells.